Xarelto (rivaroxaban) is a leading oral anticoagulant developed by Bayer and Janssen and accounts for about 45 percent of the direct oral anticoagulant (DOAC) market. It is widely prescribed for indications such as heart failure, thrombosis of the deep veins (DVT), lung embolism (PE), and postoperative prevention. As of 2026, the drug is at a […]
Read More →When patents for Reference Listed Drugs (RLDs) expire, it opens the door for generic manufacturers to offer more affordable alternatives to brand-name drugs. However, successful entry into the market requires careful preparation ahead of the patent expiration. To demonstrate that a generic drug is equivalent to its branded counterpart, companies conduct thorough clinical research. This […]
Read More →The pharmaceutical industry is undergoing a major change as patent exclusivity expires for popular drugs, highlighting vast generic drug opportunities. This shift will open up a $236 billion opportunity for generic and biosimilar manufacturers between 2025 and 2030. This significant loss of patent protection means more than just the end of exclusive rights. It will […]
Read More →